Cantor Fitzgerald Reiterates Overweight on Taysha Gene Therapies, Maintains $7 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Taysha Gene Therapies (NASDAQ:TSHA) and maintained a $7 price target.
April 18, 2024 | 1:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald maintains an Overweight rating and a $7 price target on Taysha Gene Therapies.
The reiteration of an Overweight rating and maintenance of a $7 price target by a reputable analyst firm like Cantor Fitzgerald could positively influence investor sentiment towards TSHA, potentially driving its stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100